|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001272,
umls-concept:C0018787,
umls-concept:C0022203,
umls-concept:C0026820,
umls-concept:C0027358,
umls-concept:C0029144,
umls-concept:C0205409,
umls-concept:C0376249,
umls-concept:C0441722,
umls-concept:C0999699,
umls-concept:C1521827
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1986-10-8
|
|
pubmed:abstractText |
Naloxone in concentrations ranging from 7.5 to 120 mumol l-1 reduced the beating frequency of guinea-pig isolated atria. The ED50 was 7.9 mumol l-1 for the (-)-isomer and 10.8 mumol l-1 for the (+)-isomer. Concentrations up to 120 mumol l-1 of either (-)- or (+)-naloxone did not affect the force of contraction of left atria stimulated at 1 Hz. In concentrations from 30 to 120 mumol l-1 (-)-naloxone increased the action potential (AP) duration and the functional refractory period (FRP) of papillary muscles. The resting membrane potential and the AP amplitude remained unchanged, while a small decrease of Vmax was seen with the larger drug concentrations. The influence of (+)-naloxone (120 mumol l-1) was comparable to that of the (-)-isomer. The influence of morphine (120 mumol l-1) on papillary muscle AP was small. AP duration and FRP showed a marginal prolongation while Vmax was slightly decreased. (-)-Naloxone 60 mumol l-1 had no effect on slow-response APs of K+-depolarized papillary muscles. Slow-response APs were abolished by verapamil (1 mumol l-1). In left atrial strips the prolongation of the AP duration produced by 120 mumol l-1 of either (-)- or (+)-naloxone resembled the drug effect in papillary muscles. Most of the observed changes can be explained by an inhibition of the time-dependent membrane K+ outward current, an effect of naloxone that may be classified as a Class III antiarrhythmic action. Apparently this effect is not mediated by stereospecific opioid receptors.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-1267205,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-14478533,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-233120,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-4618979,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-4694824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-4788036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6092097,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6148245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6164064,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6286027,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6289952,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6295783,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6307129,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6313291,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6317225,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6363857,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6411133,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6462378,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6538941,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6633674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6827901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6874744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-6884431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-692818,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-7031551,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-7122272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-762657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-854090,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3742157-874889
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
733-40
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:3742157-Action Potentials,
pubmed-meshheading:3742157-Animals,
pubmed-meshheading:3742157-Depression, Chemical,
pubmed-meshheading:3742157-Electric Stimulation,
pubmed-meshheading:3742157-Guinea Pigs,
pubmed-meshheading:3742157-Heart Atria,
pubmed-meshheading:3742157-Heart Rate,
pubmed-meshheading:3742157-Isomerism,
pubmed-meshheading:3742157-Male,
pubmed-meshheading:3742157-Membrane Potentials,
pubmed-meshheading:3742157-Morphine,
pubmed-meshheading:3742157-Myocardial Contraction,
pubmed-meshheading:3742157-Naloxone,
pubmed-meshheading:3742157-Potassium,
pubmed-meshheading:3742157-Verapamil
|
|
pubmed:year |
1986
|
|
pubmed:articleTitle |
Influence of the optical isomers (+)- and (-)-naloxone on beating frequency, contractile force and action potentials of guinea-pig isolated cardiac preparations.
|
|
pubmed:publicationType |
Journal Article
|
